Effect of deoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium.

This retrospective study was performed to determine the clinical usefulness of deoxyribonucleic acid (DNA) ploidy and the amount of DNA in the nucleus of the tumor cell on the prognosis of patients with carcinoma of the endometrium. Five year follow-up study was obtained for 121 patients. Flow cytometric analysis was used to determine tumor cell ploidy from paraffin-embedded specimens. Patients were grouped according to ploidy, clinical stage and grade and whether or not they received postoperative radiation. The data were subjected to a Cox proportional hazards regression analysis, and only ploidy status and clinical stage were significantly associated with survival time. Of the 121 patients observed, 44.6 per cent were aneuploid and 55.4 per cent, euploid. Preliminary chi-square analysis indicated a strong survival advantage to those patients with euploid endometrial carcinoma. The over-all five year survival rate for patients with aneuploid tumors was 53.7 per cent, as opposed to 80.6 per cent for patients with euploid tumors (p less than 0.01). Eighty-seven patients were Stage I, 39 aneuploid, 48 euploid. The five year survival rate for patients with Stage I aneuploid was 71.8 versus 85.4 per cent for those who were euploid. Twenty-one patients were Stage II; seven aneuploid and 14 euploid. The five year survival rate for aneuploid patients was 14.3 versus 85.7 per cent for euploid patients. The over-all five year survival rate for those with Stage I and II was 85.5 per cent euploid and 63.0 per cent aneuploid, p less than 0.05. Patients with Stage III or IV had poor outcome regardless of ploidy status. These data show that patients with euploid Stage I and II carcinoma of the endometrium have a significant survival advantage over patients with aneuploid tumors. We, therefore, believe that ploidy status may be used to facilitate the determination of prognosis in carcinoma of the endometrium.     

Prognostic factors of carcinoma of the male breast

The clinical course of 50 male patients with carcinoma of the breast was reviewed. The disease most commonly presented in the seventh decade of life. The clinical examination of the axilla proved to be inaccurate. Survival time was highly correlated with the pathologic stage of the lesion. The five year survival rate was 80 per cent for patients with Stage I disease and 67 per cent for those with Stage II disease. By contrast, only 25 percent of patients with Stage III disease were alive at five years and all of the patients with Stage IV disease had died of the disease by the five year point. It appears that the prognosis for male patients with carcinoma of the breast is good if the appropriate therapy is undertaken at an early stage.     

Squamous cell carcinoma of the vulva: prognostic factors influencing survival.

One hundred seventy-two cases of patients with squamous cell cancer of the vulva treated at the University of Michigan Medical Center from 1975 to 1988 are reported. The mean age was 66 years with a range of 21 to 101 years. The distribution by stage included Stage I, 65; Stage II, 44; Stage III, 50; and Stage IV, 13 patients. Groin node dissections performed on 145 patients showed negative nodes, 58%; unilateral positive nodes, 28%; and bilateral positive nodes, 14%. The distribution of patients with positive nodes was influenced by stage: Stage I, 14%; Stage II, 23%; Stage III, 72%; Stage IV, 92%. The overall cumulative 5-year survival was 71% and this was significantly influenced by stage of disease: Stage I, 94%; Stage II, 91%; Stage III, 36%; Stage IV, 26%. Stages I/II and III/IV were combined for analysis. In Stages I/II, survival was significantly influenced by tumor grade while size, patient age, and lymph node status did not influence survival. In Stage III/IV, survival was significantly influenced by tumor size, node status, and number of positive nodes while grade, patient age, and tumor location did not influence survival. Squamous cell cancer of the vulva is effectively treated with radical surgery but advanced-stage disease with regional metastases significantly alters survival.     

Preoperative and follow-up bone scans in patients with primary carcinoma of the breast.

We have attempted to evaluate the role of preoperative and postoperative bone scans in patients with localized carcinoma of the breast. The yield of positive preoperative scans in patients with Stages I and II disease is low and confounded by a relatively high percentage of false-positive results. Conversely, 16 per cent of patients with Stage III disease had evidence of bony metastasis at the time of operation. Positive bone scans were found three times as frequently in patients with axillary node involvement than in those without. Thirty per cent of those observed for varying times up to 41 months had evidence of bony metastases. Again, there was a correlation with initial clinical staging with 3.6 to 8.0 times more conversions in patients with Stage II or III disease than in those with Stage I disease. It appears that the majority of metastases to the bone become apparent within the first years. This observation deserves further study to elaborate the natural history of metastatic carcinoma of the breast.     

Changing trends in the surgical treatment of invasive carcinoma of the vulva

Twenty-nine years experience with 346 patients with invasive carcinoma of the vulva is presented. More than 90 per cent had squamous carcinoma. The primary mode of treatment was surgical. Two hundred and ninety-six patients were treated primarily with surgical treatment, 120 underwent radical vulvectomy and bilateral groin and pelvic lymphadenectomy, 133 had radical vulvectomy with bilateral groin dissection and 390 receiving nonradical procedures. Thirteen patients had radical operations plus pelvic exenteration for advanced disease. There were no intraoperative deaths, but 16 (5.4 per cent) died within 28 days of the operation. The uncorrected over-all five year survival rate was 66 per cent. In the presence of negative nodes, it was 83 per cent and with positive nodes, it was 38 per cent. Fifty per cent of those treated with exenteration are alive and disease-free at five years or more. Since one-third of the patients presented with advanced disease (Stages III and IV), earlier diagnosis and prompt referral must be encouraged to improve surgical results.     

The relationship between biliary tract infections and postoperative complications.

The hospital records of 870 consecutive patients undergoing elective biliary tract operations during an eight year period were reviewed. Bacteriologic cultures of the biliary tract obtained on 451 patients were correlated with specific biliary tract abnormalities and with postoperative complications. The incidence of positive biliary tract cultures was higher in patients with common duct disease than in those with chronic gallbladder disease without common duct disease. Choledocholithiasis and partial obstruction of the common duct are viewed as important factors in causing a high incidence of postive biliary tract cultures. Eighty-eight per cent of patients who had undergone previous biliary tract decompression procedures had positive cultures. There was no difference in the yield of postive cultures taken from the gallbladder wall and the gallbladder bile. Forty-nine per cent of patients with common bile duct disease and positive biliary tract cultures had no history of clinical cholangitis. Postoperative wound infections were more common in patients with common duct disease. The microorganism responsible for postoperative cholangitis and septicemia can usually be cultured from the biliary tract at operation. Antibiotics significantly decreased the incidence of postoperative cholangitis and septicemia.     

Results of treatment of vaginal carcinoma, 1960 to 1969 (author's transl)

Reported in this paper are 81 patients who received therapeutic irradiation by various modes for primary vaginal carcinoma, between 1960 and 1969. Severities were as follows: 23.4 per cent in Stage I, 42 per cent in Stage II, 27,2 per cent in Stage III, and 7.4 per cent in Stage IV. One single percutaneous irradiation was applied, between 1960 and 1966, while combined contact-percutaneous irradiation was used in the second half of the sixties. Five-year survival rates were 65.6 per cent for Stage I, 29 per cent for Stage II, 35.5 per cent for Stage III, and 37.6 per cent on average. The best results of combined contact-percutaneous treatment were recordable from the earlier stages. Therapies tailored to the individual concerned proved to be most effective in the context of vaginal carcinoma.     

Surgery in endometrial cancer: Age,route, and operability rate in 854 Stage I and II fresh consecutive cases: 1955–1976

Among the 641 fresh consecutive endometrial cancers treated at the Ia Clinica Ostetrica e Ginecologica of the University of Milan during the 15-year period beginning with 1955, no distinction was made between Stages I and II, owing to the inadequacy of the surgical specimens and to the relatively high proportion (29%) of radiotherapy as sole treatment. Operability rate for Stage I–II (606 cases) is 71%, as compared with 45% for Stages III and IV (35 cases); hospital mortality was 1.4%. Histologic differentiation of the tumor, vaginal recurrence, and operability rate all are inversely proportional to the age of the patients, so that 5-year actuarial survival rates fall from 88.2% (patients under 45) to 79.6% (patients over 65). The 178 patients treated with radiotherapy only show a statistically significant reduction in 5-year actuarial survival rate as compared with the 436 patients who underwent surgical or radiosurgical treatment (50.1 vs 85.3%); within the latter group 5-year actuarial survival rate is better following the vaginal (90%) than the abdominal (83.9%) route. In the period 1970–1976, characterized by more rational evaluation of tumor virulence and of patient resistance and by strict follow-up, operability rate was 94.2%, with a 5-year actuarial survival rate of 90.1 and 77.9% at Stages I and II, respectively; isolated vaginal recurrences were 0.5 and 5.1% at Stages I and II, respectively. The importance of surgery is stressed, with particular regard to the selective use of the vaginal route in poor-risk patients. Bilateral salpingo-oophorectomy is significant in the determination of the cure rate. The usefulness of preoperative intracavitary radium, postoperative external irradiation, and adjuvant progestins is not proved by the present paper and needs further study.     

Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival

OBJECTIVE: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction. METHOD: All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified. Patients meeting FIGO criteria for Stage III or IV disease were selected. Papillary serous and clear cell histology was excluded. RESULTS: Eighty-five patients were identified: 66 Stage III and 19 Stage IV. Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction. The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001). The proportion of patients with major postoperative complications (37.50% vs. 7.25%, P = 0.005), unplanned postoperative SICU admissions (31.25% vs. 7.25%, P = 0.018), and length of hospital stay exceeding 15 days (31.25% vs. 4.35%, P = 0.005) was greater in patients with suboptimal cytoreductive surgery. CONCLUSIONS: Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery. Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery. Alternative treatment options should be considered in those patients with surgically unresectable disease.     

Palliative surgical treatment of sixty-eight patients with carcinoma of the head of the pancreas

A retrospective study is presented of 68 patients who underwent biliary enteric bypass procedures for carcinoma of the head of the pancreas between the years of 1960 through 1975. Forty patients underwent some form of biliary enteric bypass only. Twenty-six patients were treated with concomitant gastrojejunostomy, and only two patients in this group underwent vagotomy. Two patients underwent gastrojejunostomy for obstruction at the gastric outlet without jaundice. Five operative deaths occurred among the 40 patients who underwent solely some form of biliary enteric bypass procedure, and three deaths occurred among the 26 patients who underwent concomitant gastrojejunostomy. The over-all operative mortality for biliary enteric bypass procedures was eight deaths among 68 patients. Obstruction of the duodenum developed in seven patients after undergoing a biliary enteric bypass operation. The mean postoperative interval for the development of complications was 5.57 months. All but one patient underwent a second operation, with no operative deaths. Among the 26 patients treated with concomitant gastrojejunostomy, obstruction developed in two patients because of anastomotic failure; there was massive upper gastrointestinal tract bleeding from a marginal ulcer in four patients, and one patient had a perforated marginal ulcer. The mean survival time after biliary enteric bypass was 6.69 months and after combined biliary enteric bypass and gastrojejunostomy, 9.90 months. The over-all mean survival time was 8.00 months.     

Surgical treatment of vulvar cancer.

59 (80%) of 74 patients with vulvar cancer treated at the University Department of Obstetrics and Gynecology in Ljubljana in the period 1973-85 underwent radical vulvectomy with bilateral inguinofemoral lymphadenectomy, and 15 (20%) patients single vulvectomy because of advanced age and poor general condition. Histologically there were 69 cases of squamous cell carcinoma, 1 adenocarcinoma, 3 malignant melanoma and 1 rhabdomyosarcoma. 52% of the patients were classified as Stage I, 41% Stage II and 7% Stage III. Positive inguinofemoral nodes were observed in 24% (6.5% in Stage I, 35% in Stage II and 80% in Stage III). The total 5 year survival rate was 70% (83% in Stage I, 61% in Stage II and 20% in Stage III). The 5 year survival rate in the patients with negative nodes was 80%, and in cases with positive nodes only 50% in spite of postoperative irradiation. None of the 3 patients with melanoma survived 2 years nor did the patient with rhabdomyosarcoma. There was no case of primary mortality. Nowadays the cure rate for vulvar cancer is higher especially owing to the improvement of operability. The problem of lymphatic and distant metastases still remains unresolved.     

Carcinoma of the head of the pancreas.

Optimal treatment for unresectable carcinoma of the pancreas remains controversial. This study was done to examine the relationship between perioperative jaundice and postoperative morbidity, and type of palliative biliary bypass and postoperative morbidity and jaundice clearance. Seventy-six patients with obstructive jaundice secondary to carcinoma of the head of the pancreas were studied. Forty-nine patients underwent one of four different types of palliative bypass: 1, cholecystojejunostomy (n = 22); 2, choledochojejunostomy (n = 11); 3, choledochoduodenostomy (n = 9), and 4, cholecystoduodenostomy (n = 7). Age, sex and preoperative health status were similar for all operative groups, as well as for those with and without postoperative morbidity. The postoperative complication rate was 33 per cent and there was one postoperative death. Length of preoperative jaundice and peak preoperative bilirubin levels were independent of morbidity. Postoperative morbidity was similar for each type of bypass used and no significant difference was found when cholecystoenteric (1 and 4) and choledochoenteric (2 and 3) bypass were compared. The results of this study support the view that postoperative morbidity is not directly related to the presence of jaundice preoperatively. Furthermore, the rate of jaundice clearance and the occurrence of postoperative complications are not dependent on the type of bypass used.     

Radiation therapy in primary carcinoma of the vagina

A retrospective analysis of 32 patients with carcinoma of the vagina treated with curative radiotherapy between 1965 and 1981 is presented. Squamous cell carcinoma was the most common histologic type, found in 78% of the patients. Patients were staged according to the FIGO system. Stage I and II disease was found in 8 and 18 patients, respectively. Six patients had either Stage III or IV disease. The absolute survival rate was 100% for Stage I and 72% for Stage II patients. The pattern of failure was analyzed. All patients who failed had done so within 14 months of completion of treatment. Treatment failure in the pelvis occurred only in 16% of the patients with early disease (Stages I and II) while 81% of the patients with late stage had failed in the pelvis.     

Adenocarcinoma of the colon and rectum in patients less than 40 years of age

From 1962 to 1988, 50 of 801 patients with adenocarcinoma of the colon and rectum treated at the National Naval Medical Center were less than 40 years old. Symptoms were present in 47 of the younger patients at presentation. The mean duration of time from the onset of symptoms to diagnosis in this group was 4.9 months. Risk factors for carcinoma of the colon and rectum were identified in 14 of 50 patients less than 40 years old. A significantly greater proportion of patients less than 40 years old had Stage C disease compared with the older group of patients (42 versus 22 per cent, p = 0.014). Stage B disease was more common in patients more than 40 years of age (44.8 versus 26.0 per cent, p = 0.014). The proportion of patients with Stages A and D disease was similar in both age groups. The cumulative survival rate in this group at five and ten years was 43 and 34 per cent, respectively. The five year survival rate in patients less than 40 years old with Stage B disease was 76 per cent and with Stage C disease, 37 per cent. All young patients with Stage D disease were dead at 28 months. Synchronous and metachronous carcinomas of the colon and rectum were uncommon in patients less than 40 years old. Patients less than 40 years of age with carcinoma of the colon and rectum are usually symptomatic and have advanced disease at the time of presentation. Survival time for these patients for each stage of disease is similar to the over-all population of patients with carcinoma of the colon and rectum.     

Postresection stage grouping in carcinoma of the lung.

The postsurgical treatment classification and staging system for carcinoma of the lung has been evaluated in a series of 403 patients admitted to a completed prospective randomized adjuvant cancer chemotherapy trial conducted by the Veterans Administration Surgical Adjuvant Group. The proposed T, N and M classification suggested by the American Joint Committee for Cancer Staging and End Results Reporting is supported. However, the stage groupings as suggested by the Committee fails to separate adequately the various prognostic groups. This appears to be better accomplished by the stage grouping modification suggested by the Radiation Therapy Oncology Group. In the latter schema, the five year survival rate of patients with postsurgical treatment Stage I disease is 40.9 per cent; Stage II, 26.2 per cent, and Stage III, 10.5 per cent. In the Joint Committee classification, these survival rates are 30.8 per cent, 25.5 per cent and 10.5 per cent, respectively. In addition, 18 patients with undifferentiated small cell carcinoma were also evaluated. The long term survival of three of sixe patients with small peripheral lesions without metastatic lymph node involvement supports the opinion that resection of these specific lesions continues to be the treatment of choice.     

Surgical treatment of advanced carcinoma of the esophagus

This report was done to evaluate the role of surgical treatment of locally advanced carcinoma of the esophagus. All 32 patients had histologically proved epidermoid carcinomas of the esophagus. The post-operative one and two year survival rates and median survival time were 34.6 and 17.3 per cent and 199 days for those in the group undergoing esophagectomy, zero per cent and 55 days for those in the group with bypass and zero per cent and 80 days for those undergoing formation of a stoma. Thirty day postoperative mortality rates were zero per cent for the esophagectomy group, 25.0 per cent for the stoma group and 33.3 per cent for the bypass group. When calculated from the date of diagnosis, the one and two year survival rates and the median survival time were 50.2 and 16.7 per cent and 296 days for the esophagectomy group, 16.7 and zero per cent and 196 days for the bypass group, 25.0 and zero per cent and 142 days for the stoma group and zero per cent and 142 days for the group who did not undergo surgical treatment. Complication related postoperative deaths occurred in 14.8 per cent of the 27 patients operated upon. For those in the esophagectomy group, it was 5.9 per cent, and for the bypass group, 50.0 per cent. Swallowing was improved in 58.8 per cent after esophagectomy, but in none of the patients was swallowing restored after the bypass procedures. When the invasion spared the aorta or major respiratory tract, postoperative survival time after esophagectomy was significantly better. Considering the short postoperative survival time and frequent complications, bypass procedure should not be the final resort after nonsurgical treatment.     

Ovarian clear cell adenocarcinoma

The clinical and pathologic features of 29 cases of ovarian clear cell adenocarcinoma (OCCA) were studied to evaluate outcome and potential predictors of survival. Patients' ages ranged from 30 to 89 years (median, 54 years). The study group, using the FIGO classification, consisted of 10 Stage I, 5 Stage II, 7 Stage III, 5 Stage IV, and 2 unstaged patients. Previous or concurrent endometriosis was noted in 45% of patients. Three patients (10.3%) had hypercalcemia. Only stage and the presence of macroscopic residual disease had a statistically significant association with survival. Stage I and II patients experienced a survival similar to a group of 305 patients with adenocarcinomas of non-clear cell type in our ovarian cancer registry with the exception of the very poor survival among Stage IC OCCA patients. Patients with Stage III and IV OCCA had a worse survival than non-OCCA registry patients of similar stage. Few objective responses to adjuvant chemotherapy could be demonstrated in these high-stage OCCA patients. Further study of postoperative adjuvant therapies is warranted.     

A comparison of cefotaxime versus cefamandole in prophylaxis for surgical treatment of the biliary tract

Fiscal considerations prompted comparison of cefotaxime (a third generation cephalosporin) with cefamandole (a second generation cephalosporin) for prophylaxis in the surgical treatment of the biliary tract. One hundred and eight patients who underwent an operation upon the biliary tract received three 1 gram doses of cefotaxime (54 patients) or cefamandole (54 patients) at induction of anesthesia and then one and three hours later. The study was prospective, blinded and randomized. The groups (cefotaxime versus cefamandole) were statistically comparable for age, sex, diagnosis, type and duration of operation and positive cultures. The most prevalent bacteria isolated from qualitative aerobic and anaerobic cultures of bile and the wall of the gallbladder were Escherichia coli, Streptococcus and Klebsiella. The incidence of bactibilia in patients with one of these conditions was: 75 per cent for cancer; 69 per cent for patients more than 60 years old; 33 per cent for jaundice; 58 per cent for pancreatitis; 60 per cent for exploration of the common bile duct, and 22 per cent for acute cholecystitis. Microbiologic agar diffusion assays of tissue from the wall of the gallbladder, subcutaneous fat and rectus muscle and samples of bile and serum obtained 30 minutes after the second dose of antibiotic showed a statistically significant greater concentration of cefamandole in the wall of the gallbladder. Otherwise there was no difference between the concentration of cefamandole and cefotaxime. The groups showed no statistical difference for temperature of more than or equal to 38 degrees C. on two consecutive measurements, postoperative wound and urinary infections, postoperative hospital stay and days in the intensive care unit and incidence of readmission within a month. Prophylactic use of cefotaxime in a three dose regimen provided no advantage in prophylaxis compared with cefamandole.     

Combination chemotherapy in advanced adenocarcinoma of the fallopian tube

Advanced adenocarcinoma of the fallopian tube has a poor prognosis, with 5-year survival rates commonly less than 20%. Since 1980, we have managed 12 patients with disseminated tumor with combination chemotherapy following surgical cytoreduction. Analogous to the International Federation of Gynecology and Obstetrics staging of ovarian carcinoma, 3 patients were classified in Stage II, 8 in Stage III, and 1 in Stage IV. Ten patients received cisplatin-containing regimens. The 3 Stage II patients, without measurable disease after primary surgery, had an indeterminate response to chemotherapy. In Stages III-IV there were 4 complete responses (3 confirmed by second-look laparotomy) and 2 partial responses, for an overall response rate of 67%. Disease progressed in 2 patients and was stable in 1 patient. After median follow-up of 3.5 years, 4 of the Stage III-IV patients have no evidence of disease, 1 is alive with disease, and 4 are dead.     

Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR)

In an attempt to identify those parameters which represent predictors of clinical outcome, a retrospective review of patients with epithelial ovarian carcinoma who were primarily treated with whole abdominal irradiation (WAR) following staging laparotomy was performed. Complete records with extensive long-term follow-up were available on 102 patients treated from 1962 through 1974. Histopathologic review excluded 18 patients with lesions of low malignant potential. Of the remaining 84 cases there were 12 Stage I (14%), 23 Stage II (27%), 45 Stage III (54%), and 4 Stage IV (5%). Measure of completeness of surgical resection was expressed as the largest diameter of residual gross tumor. Following primary surgical debulking Stages II and III patients, 24 patients had no gross residual disease, 24 patients had less than 2 cm of residual disease, and 20 patients had greater than 2 cm of residual disease. For Stages II and III patients together, 5- and 10-year actuarial survivals were: No gross residual, 69% and 59%; less than 2 cm, 48% and 42%; and greater than 2 cm, 15% and 10%. The technique of administration of WAR did not appear to influence survival. The results of this review support the concept that in selecting WAR for primary treatment of ovarian carcinoma, completeness of cytoreductive surgery should be considered. These data justify a prospective randomized study in patients with minimal residual disease following staging laparotomy comparing WAR with current first-line combination chemotherapy.